

Rhythm Top 20 Shareholder Update

29 January 2021, Melbourne: Rhythm Biosciences Limited (ASX: **RHY**) (**Rhythm** or the **Company**) is pleased to provide an update of the Top 20 shareholders as at 28 January 2021 (Table 1 below).

At the request of shareholders, the Company has considered and decided that a Top 20 shareholder list be provided as an update to the general market via the ASX, given the increased trading activity in RHY subsequent to the release of the FY'20 Annual Report.

RANK	NAME	NO. OF SHARES	% ISSUED CAPITAL
1	WEBINVEST PTY LTD	16,666,667	8.27
2	NEWFOUND INVESTMENTS PTY LTD	10,733,333	5.33
3	FERNDAL SECURITIES PTY LTD	10,400,000	5.16
4	LOUMEA INVESTMENT PTY LTD	9,915,000	4.92
5	NORTHERN STAR NOMINEES PTY LTD	7,200,000	3.57
6	MRS SARAH CAMERON	6,751,781	3.35
7	ROJO NERO CAPITAL PTY LTD	4,166,668	2.07
8	GIOKIR PTY LTD	3,400,000	1.69
9	JAWAF ENTERPRISES PTY LTD	3,150,000	1.56
10	MR HSIEN MICHAEL SOO	3,000,000	1.49
11	MR DANIEL EDDINGTON & MRS JULIE EDDINGTON	2,560,000	1.27
12	COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION	2,500,000	1.24
13	MS NATALIE LOUISE PATTERSON	2,416,666	1.20
14	DR GAVIN JAMES SHEPHERD & MRS CATHERINE SHEPHERD	2,150,000	1.07
15	E & W NOMINEE PTY LTD	2,144,668	1.06
16	MOWBRICK PTE LIMITED	2,130,000	1.06
17	GARNSWORTHY PENSION FUND PTY LTD	2,050,000	1.02
18	ARDROY SECURITIES PTY LTD	1,760,000	0.87
19	DC & PC HOLDINGS PTY LTD	1,750,000	0.87
20	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	1,672,277	0.83

Table 1: Top 20 Shareholder list

Released with the authority of the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

About Rhythm Biosciences

Rhythm Biosciences (ASX: RHY) is a transformative, predictive diagnostics company, specialising in early cancer detection. Rhythm's initial business pursuit is centred upon technology originally developed by the CSIRO and involves the development and commercialisation of a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower cost. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be used easily by laboratories without the need for additional operator training or additional infrastructure. ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer via increasing current screening rates.

Globally, over 850,000 people die from colorectal cancer each year. Colorectal cancer is typically diagnosed at a later stage when there is a poor prognosis for long-term survival. Annual estimated unscreened 50-74-year old's is estimated at +130m for the US, EU and AU alone, with this market potential being more than \$6.5b.